Drug Detection And Identification Articles & Analysis
17 news found
As an expert in providing solutions to assist virology and microbiology research, Creative Diagnostics has announced the expansion and enhancement of its comprehensive Drug Discovery Services to help scientists advance antiviral therapeutic development, including target selection and validation, hit selection and optimization, and preclinical development. These new services will support ...
The need for high-quality pharmaceutical development services has never been more pressing. Therefore, in a swift response to such demand, CD Formulation has recently rolled out its new Pharmaceutical Formulation Characterization Testing (PFCT) services, a move aiming to help ensure that the newly developed pharmaceutical products are stable, effective, and in compliance with the regulatory ...
Given the significance of glycosylation in protein drugs, CD BioGlyco offers clients thorough services for characterization of glycosylation in protein drugs. Identification and quantification of various monosaccharides, including fucose, mannose, and galactose. ...
Pronalyse is a new division of Creative Proteomics, which is an integrated CRO company with rich experience in providing drug development services. Building on its years of experience, Creative Proteomics Pronalyse announces the launch of its metabolite identification services of biopharmaceuticals for an accurate and efficient analysis of the metabolism for your biological drugs in vivo. The ...
Iktos, a company specialized in Artificial Intelligence (AI) for new drug design and Sygnature Discovery, a leading integrated drug discovery CRO headquartered in Nottingham, UK, with expertise across a range of therapeutic and biological target classes today announced a collaboration agreement in AI for new drug design. Under the 3-year agreement, Sygnature will deploy Iktos’ de novo ...
ByIktos
CD BioSciences, a leading customer-focused biotechnology company based in New York, recently introduces a series of GPCR Drug Discovery services to customers in their GPCR drug discovery and development projects. G protein-coupled receptors (GPCRs), also known as seven-(pass)-transmembrane domain receptors, play a pervasive physiological and pathophysiological role in humans. They are major ...
Iktos, a company specialized in Artificial Intelligence (AI) for new drug design, and Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business that provides comprehensive healthcare services to improve the quality of life, today announced a strategic collaboration agreement in Artificial Intelligence for new drug design. Under the agreement, Iktos generative ...
ByIktos
Iktos, a company specialized in Artificial Intelligence (AI) for new drug design today announced a collaboration agreement with Ono Pharmaceuticals Co., Ltd., a leading pharmaceutical company based in Japan with a focus on innovative medicines dedicated to the fight against disease and pain. Under the agreement, Iktos will apply its de novo ligand and structure-based generative modelling ...
ByIktos
Transcriptomics enables genome-wide analysis of transcription at single-nucleotide resolution, including determination of the relative abundance of transcripts, unbiased identification of alternative splicing events and post-transcriptional RNA editing events, and detection of single nucleotide polymorphisms (SNPs). ...
Combines Exscientia’s leading AI-driven drug identification and design capabilities with GT Apeiron’s expertise in cyclin-dependent kinase (CDK) targets for oncology. Expands existing CDK7 drug discovery partnership with additional CDK targeting drugs Oxford & Shanghai – July 21st, 2021 – Exscientia, an AI-driven pharmatech company with a mission to revolutionise how ...
Canaquest Medical Corp (OTC PINK:CANQF) (the “Company” or “CanaQuest“), an award-winning Life Science/Pharmaceutical company developing formulations combining cannabinoid molecules with pharmaceutical-grade botanical compounds, today announced the filing of its International Patent, trade named Mentanine, which has demonstrated at least 10-times (10X) the efficacy compared ...
Pronalyse is a new division of Creative Proteomics, which is an integrated CRO company with rich experience in providing drug development service for over 10 years. With years of experience in offering professional and high-quality products for academic use and pharmaceutical industries, Creative Proteomics announces diversified PEGylated protein analysis technologies, which can solve important ...
Canaquest Medical Corp (OTC PINK:CANQF) (the “Company” or “CanaQuest“), an award-winning Life Science/Pharmaceutical company developing health and wellness products combining cannabinoid molecules with pharmaceutical-grade botanical compounds, today announced that Rob Rinderman has joined CanaQuest as its new Director of Communications. Mr. Rinderman will focus on managing ...
CANAQUEST MEDICAL CORP (OTC PINK:CANQF) (the “Company” or “CanaQuest“), a Life Science/Pharmaceutical Company developing health products utilizing cannabinoid molecules and other botanical compounds (pharmaceutical grade), today announced it has been awarded the International CBD Life Science R & D Excellence Award 2020 by Global Health & Pharma, United Kingdom, a ...
Canaquest Medical Corp (OTC PINK:CANQF) (the “Company” or “CanaQuest“), a Life Science/Pharmaceutical Company developing health products utilizing cannabinoid molecules and other botanical compounds (pharmaceutical grade), today announced that Fundamental Research Corp (“FRC”), one of the world’s largest independent research houses, has launched coverage ...
Canaquest Medical Corp (OTC Markets: “CANQF”) (the “Company” or “CanaQuest”), a Life Science/Pharmaceutical Company developing health products utilizing cannabinoid molecules and other botanical compounds (pharmaceutical grade), is pleased to announce its new partnership with the Canadian Cannabis Dispute Resolution Centre (“CCDRC”), a national ...
CANAQUEST MEDICAL CORP (OTC PINK:CANQF) (the "Company" or "CanaQuest"), a clinical-stage life sciences company focused on drug discovery and development of next-generation targeted cannabinoid therapeutics for the central nervous system (CNS), today announced Statistically Significant efficacy results from the Clinical Dose & Efficacy Study ("Study") conducted by Dr. W McIntyre Burnham, ...